Trial reportFrontiers in public health2026
Individual-level HPV vaccination verification in Botswana: lessons learned from implementation of the HOPE II trial.
Trial report in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) estimated 660,000 new cervical cancer cases and 350,000 deaths globally in 2022, with over 90% occurring in low- and middle-income countries (LMICs). Global elimination targets call for vaccination of >90% of girls against human papillomavirus (HPV) by age 15 by 2030. While Botswana's national policy aligns with these targets, progress monitoring is constrained by fragmented, predominantly paper-based health information systems. We describe our experience verifying individual-level HPV vaccination status among adolescent girls and young women living with HIV (AGYWLWH) in Botswana. This activity was conducted to determine eligibility for the HOPE II trial, a randomized controlled study evaluating the efficacy of a single-dose nonavalent HPV vaccine. Verification followed the national rollout of school-based HPV vaccination in 2015, targeting girls aged 9-13 years. Participants provided pre-screening consent for review of vaccination records held in school health systems, Ministry of Health (MoH) registers, and participant-held vaccination cards where available. We sought HPV vaccination records for 80 potential participants across 80 schools and 68 clinics. Only 15 participants (18.8%) had verifiable records: 2 (2.5%) retained vaccination cards, 4 (5.0%) had documentation in school records, and 9 (11.3%) had entries in MoH registers. Most school records were incomplete or missing, and several sites reported loss or disposal of records due to relocation, fire damage, or storage constraints. These findings highlight critical gaps in HPV vaccination documentation. Strengthening electronic immunization registries, standardizing record transfer, and improving data integration could enhance monitoring and support equitable progress toward cervical cancer elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.